PAM
ADMA icon

Premier Asset Management’s ADMA Biologics ADMA Stock Holding History

Premier Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-22,006
Closed -$63K – 128
2020
Q1 		$63K Buy
+22,006
New +$76.1K 0.03% 107

Other funds holding ADMA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Premier Asset Management's ADMA Position: Q2 2020 in Review

Premier Asset Management sold out of ADMA Biologics (ADMA) in Q2 2020, closing a stake of 22,006 shares — an estimated $63K sold.

Premier Asset Management first reported a position in ADMA in Q1 2020 and held it in 1 quarter. The position peaked at $63K in Q1 2020. 95 funds tracked by Wall St. Rank hold ADMA as of Q2 2020.

  • Premier Asset Management reported no remaining ADMA Biologics position as of Q2 2020 after selling out during the quarter.
  • Premier Asset Management sold 22,006 ADMA Biologics shares in Q2 2020, an estimated $63K.
  • Premier Asset Management first reported a position in ADMA Biologics in Q1 2020 and held it in 1 quarter.
  • Premier Asset Management's ADMA Biologics position peaked at $63K in Q1 2020.
  • 95 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2020.

Based on Premier Asset Management's 13F filing for Q2 2020, filed 31 Jul 2020.